Publications by authors named "E Outhwaite"
Article Synopsis
- - BEECH study explored the effectiveness of capivasertib, an oral AKT inhibitor, combined with paclitaxel for treating advanced ER+/HER2- breast cancer, specifically focusing on patients with a PIK3CA mutation.
- - The study consisted of a safety phase with 38 patients and a randomized phase involving 110 women, aiming to evaluate safety and progression-free survival (PFS).
- - Results showed capivasertib was tolerable, with a median PFS of 10.9 months in the treatment group compared to 8.4 months in the placebo group, though statistical significance was not reached, indicating no major impact on treatment outcomes.
